Summit Therapeutics said its lead lung cancer drug, ivonescimab, outperformed AstraZeneca's immunotherapy Imfinzi in a Phase 3 trial [1, 2].
The result marks a potential shift in the treatment of late-stage lung cancer. If the drug gains regulatory approval, it could challenge the market dominance of established immunotherapies by offering improved patient outcomes.
Ivonescimab is licensed from Akeso [1, 2]. The late-stage trial was conducted across multiple international sites to test the efficacy of the drug against Imfinzi [1, 2]. According to the trial data, ivonescimab demonstrated a survival rate approximately 15% higher than that of Imfinzi [2].
This survival advantage was described as statistically significant [1, 2]. The findings have led to increased investor optimism regarding the commercial viability of the treatment. Market reactions followed the release of the data, which originally surfaced in late 2024 [1, 2].
Summit Therapeutics said it continues to move forward with the development of the drug based on these results. The company has not yet disclosed the specific international locations where the Phase 3 trial took place [1, 2].
Industry analysts are monitoring the progress of ivonescimab as it moves toward potential regulatory filings. The success of the trial suggests that the dual-action approach of the drug, licensed from Akeso, may be more effective than the current standard of care provided by AstraZeneca's treatment [1, 2].
“ivonescimab demonstrated a survival rate approximately 15% higher than that of Imfinzi”
The success of ivonescimab in a head-to-head Phase 3 trial suggests a new benchmark for efficacy in late-stage lung cancer treatment. By outperforming a leading drug like Imfinzi, Summit Therapeutics and Akeso may disrupt the current immunotherapy landscape, potentially forcing a shift in clinical guidelines if the drug receives regulatory approval.
